Low Testosterone in Obese Men Is Usually Reversible Without Hormone Therapy

Low serum testosterone in men with obesity is one of the most commonly mismanaged findings in modern endocrinology. This case-based clinical review from Australian andrology experts — published in the Journal of Clinical Endocrinology and Metabolism — provides a detailed framework for distinguishing true pathologic hypogonadism from the far more common 'pseudo-hypogonadism of obesity,' a reversible and eugonadal condition that does not warrant testosterone replacement therapy.

The central teaching case involves a 37-year-old man presenting with fatigue, reduced libido, erectile dysfunction, poor exercise recovery, and difficulty losing weight. At baseline, he weighed 118 kg (BMI 36 kg/m²) with a waist circumference of 112 cm. His serum testosterone was 147 ng/dL (5.1 nmol/L), well below the reference range of 231–808 ng/dL. Critically, his SHBG was low at 14 nmol/L (NR 12–50), and LH and FSH were entirely normal at 2.1 and 3.2 IU/L respectively. He also had elevated liver enzymes (ALT 107 U/L, AST 56 U/L), fasting glucose of 120 mg/dL, HbA1c of 6.2%, elevated triglycerides, and was treated for OSA and hypertension.

After clinically significant weight loss — reducing to 94 kg (BMI 28.7 kg/m²) — his serum testosterone tripled to 467 ng/dL (16.2 nmol/L), rising fully into the normal range. SHBG increased proportionally to 33 nmol/L. Liver enzymes normalized dramatically (ALT 18, AST 20 U/L), fasting glucose fell to 93 mg/dL, HbA1c dropped to 5.4%, and triglycerides improved to 1.7 mmol/L — all without testosterone treatment. These changes demonstrate that the low testosterone was a downstream consequence of obesity-related metabolic dysfunction, not an independent gonadal defect.

The mechanistic explanation is well-established: obesity drives hyperinsulinemia, hypertriglyceridemia, and hepatic steatosis, all of which suppress hepatic SHBG production. Since SHBG is testosterone's principal circulating carrier protein, lower SHBG directly reduces total measured testosterone. However, the pituitary gonadotropins LH and FSH — which function as the most sensitive tissue androgen sensors in the body (analogous to TSH for thyroid status) — remain normal, confirming intact testicular and hypothalamic-pituitary function. Stimulation testing with hCG and GnRH in research settings has confirmed both organs remain fully responsive. Even in class III obesity (BMI >40 kg/m²), where reduced LH pulse amplitude has been observed, these changes reverse with weight loss.

The authors mount a strong evidence-based argument against routine use of free testosterone measurements, calling the free testosterone hypothesis 'conceptually flawed.' They note that unbound testosterone is equally accessible to degradation sites as to target tissues, that reference dialysis-based free testosterone assays are costly and rarely available, and that calculated free testosterone estimates using various formulas are consistently inaccurate due to non-harmonized SHBG immunoassays, differing binding affinity constants, and the absence of a certified reference standard.

The clinical implications are substantial. The authors document a 100-fold increase in testosterone prescribing over three decades without any new approved indications, attributing much of this to misclassification of obesity-related pseudo-hypogonadism as true androgen deficiency. Unjustified testosterone treatment carries real risks: infertility through suppression of spermatogenesis, elevated hematocrit requiring venesection, a prothrombotic state, and physiological testosterone dependence. The recommended approach is structured lifestyle intervention targeting weight loss, optimization of OSA, T2DM, depression, and metabolic comorbidities, and rationalization of any concomitant medications known to lower testosterone.